Supernus Pharmaceuticals, Inc. has officially completed its merger with Indivior Pharmaceuticals, Inc., a significant event that reshapes the company's future. This merger, effective November 2, 2026, allows Supernus to become a wholly owned subsidiary of Indivior, which has been renamed Supernus, Inc. The merger signifies a strategic move to enhance the combined company's capabilities in the pharmaceutical industry.

Supernus Pharmaceuticals, based in Rockville, Maryland, operates under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company has been active in the pharmaceutical sector, focusing on developing and commercializing products for the treatment of central nervous system disorders. This merger aligns with the broader trend of consolidation in the pharmaceutical industry, where companies seek to strengthen their market positions through strategic partnerships and acquisitions.

According to the recent SEC filing (accession number 0001104659-26-121014), the merger was executed under the Agreement and Plan of Merger dated August 1, 2026. The merger involved Indivior’s subsidiary, Artemis Merger Sub Inc., which merged with Supernus, leading to Supernus continuing as the surviving corporation. As a result of this transaction, shares of Supernus common stock will no longer be listed on the Nasdaq Stock Market.

The filing indicates that the merger was not just a structural change but also involved significant financial maneuvers. A Credit Agreement was established, providing a senior secured term loan facility of $650 million, which was fully borrowed on the closing date. This funding will be utilized for various purposes, including refinancing existing debt and covering costs associated with the merger.

The merger's completion is expected to impact various stakeholders, including employees, shareholders, and customers. Employees of Supernus may see changes in their roles and responsibilities as the company integrates into Indivior. Shareholders of Supernus will receive shares of Indivior common stock in exchange for their holdings, with an exchange ratio of 1.5401 shares of Indivior for each share of Supernus. This transition is likely to create new dynamics within the combined company as it seeks to leverage the strengths of both entities.

Looking ahead, the filing does not specify any immediate next steps following the merger's completion. However, it is anticipated that the combined company will focus on integrating operations and exploring new opportunities in the pharmaceutical market. The merger is expected to enhance the operational capabilities and market presence of the newly formed Supernus, Inc., positioning it for future growth and success in the competitive pharmaceutical industry.